USPSTF guidance on smoking cessation in nonpregnant adults: which statement is true?

USPSTF guidance on smoking cessation in nonpregnant adults: which statement is true?

• A. Clinicians should ask about tobacco use and provide behavioral interventions and FDA-approved pharmacotherapy.
• B. Pharmacotherapy alone without behavioral interventions is recommended.
• C. Only provide brief advice without interventions.
• D. No guidance exists.

Answer: (A)

The important idea is that quitting tobacco is most effective when a clinician actively engages the patient with both identification and support. For nonpregnant adults who use tobacco, USPSTF guidelines emphasize screening for tobacco use and then providing or referring to evidence-based cessation help. This help combines two proven elements: behavioral interventions (counseling, ongoing support, and guidance tailored to the patient) and FDA-approved pharmacotherapy (such as nicotine replacement products, varenicline, or bupropion). The reason this is the best approach is that behavioral support helps patients develop coping strategies and stay motivated, while medications reduce withdrawal symptoms and cravings, leading to higher quit rates. When used together, they work better than either component alone. Brief advice alone, while beneficial, is not as effective as offering a structured cessation program, and pharmacotherapy without behavioral support misses the added benefit of counseling. The guidance thus clearly supports asking about tobacco use and providing a combined plan of behavioral interventions plus FDA-approved medications.

The important idea is that quitting tobacco is most effective when a clinician actively engages the patient with both identification and support. For nonpregnant adults who use tobacco, USPSTF guidelines emphasize screening for tobacco use and then providing or referring to evidence-based cessation help. This help combines two proven elements: behavioral interventions (counseling, ongoing support, and guidance tailored to the patient) and FDA-approved pharmacotherapy (such as nicotine replacement products, varenicline, or bupropion). The reason this is the best approach is that behavioral support helps patients develop coping strategies and stay motivated, while medications reduce withdrawal symptoms and cravings, leading to higher quit rates. When used together, they work better than either component alone. Brief advice alone, while beneficial, is not as effective as offering a structured cessation program, and pharmacotherapy without behavioral support misses the added benefit of counseling. The guidance thus clearly supports asking about tobacco use and providing a combined plan of behavioral interventions plus FDA-approved medications.